Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003777 · ClinicalTrials.gov registry record · Phase 2

Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer

A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.

Terminated
Registry status
Phase 2
Development phase
35
Enrollment target

NCT00003777: Clinical Trial Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.

NCT00003777 is a Phase 2 study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003777, a Phase 2 study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.

TERMINATED
Registry status
Phase 2
Development phase
35 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as amifostine may prevent the side effects of radiation therapy. Combining more than one drug and combining radiation therapy and surgery with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining surgery, radiation therapy, and combination chemotherapy in treating patients who have recurrent head and neck cancer that has been treated previously with radiation therapy.

Interventions

  • DRUG cisplatin
  • DRUG fluorouracil
  • RADIATION radiation therapy
  • DRUG amifostine trihydrate
  • PROCEDURE surgical procedure

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 1998-12
Est. Completion 2001-04-20
Phase Phase 2

Why NCT00003777 stopped before completion

NCT00003777 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).

The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.

NCT00003777 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00003777 about?

NCT00003777 is a clinical study titled "Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as amifostine may prevent the side effects of radiation therapy. Combining more than one drug and combin...

What is the current status of trial NCT00003777?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 1998-12. Estimated completion is 2001-04-20.

What interventions are being tested in trial NCT00003777?

The interventions under investigation include: cisplatin (DRUG), fluorouracil (DRUG), radiation therapy (RADIATION), amifostine trihydrate (DRUG), surgical procedure (PROCEDURE).

Who is sponsoring clinical trial NCT00003777?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00003777's enrollment target sits among peer trials

35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01697371 · 35 participants · NA

    Proton Therapy in the Treatment of Liver Metastases

  • NCT01940757 · 35 participants · Phase 1

    Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

  • NCT02235857 · 35 participants · NA

    Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

  • NCT02637934 · 35 participants · Phase 1

    Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00003777, the US trial registry maintained by the National Library of Medicine. NCT00003777 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.